Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Aug 03, 2018 12:13pm
175 Views
Post# 28410816

RE:Info on the rights - Bullish news

RE:Info on the rights - Bullish newsThe board members are taking advantage of the suppressed share price, we need others to follow their example.

When you write "(more financial than operational)" what do you mean? Generally they need to set up or already have infusion rooms?? They have the staff (nurses??) to administer the process??? They have to set up the infrastructure/equipment??? They are slow to fit the process into their schedule?Not sure what you mean.

Elephant in the room!!! Did you ask for updated patient number? :)
.... or ask when the next update in the number might happen?

SPCEO1 wrote: I called Luc to ask about the rights issued to threee board members, He indicated that these rights can be taken as payment instead of cash for a board members payment from serving on the board. Clearly a bullish development that these board members prefer TH shares to cold hard cash.

He was in a rush but I did ask briefly about sales, naturally. He said the trend is really good and that the Taimed sales data can be impacted by shipping or accounting issues. I took that to mean there may have been an order at the end of the month that did not get recorded in July. If I am right about that I guess if August Taimed sales are quite large, we will need to discount that as it may incorporate orders fro more than just August. 

The only sales issue they are contending with is getting the doctors set up to do infusions as this is the first HIV drug that is an infusion. The patients are there and the doctors like the drug - once they get the infusion systems set up (more financial than operational), that is likely to help on the sales front.

He was pretty happy with Egrifta sales as well.

Basically, Luc was pretty happy. And it is always good when Luc is happy. You may have heard the line "When Mama's happy, everybody's happy". I think you can just say in this case, "When Luc is happy, everybody is happy".


Bullboard Posts